QuoTrend
DashboardScreenCompareStrategiesPortfolioSectorsHeatmapsInsiderFuturesForexCryptoCalendarNews
DashboardScreenCompareStrategiesPortfolioSectorsHeatmapsInsiderFuturesForexCryptoCalendarNewsMore
⌘K
Help
QuoTrend
PAGEHome
HomePricingContactHelpTermsPrivacy
Quotes delayed 15 minutes for NASDAQ, NYSE and AMEX.
© 2026 QuoTrend
Screen

CNTA

QT48Centessa Pharmaceuticals plc
NASDAQ·Healthcare·Biotechnology·UK
Latest market price
40.02
+0.15+0.38%
OverviewShort InterestFilings
CNTAQT48Centessa Pharmaceuticals plc·NASDAQ
OverviewShort InterestFilings
40.02+0.38%
TA
Loading chart...
Screen all →
VRTX-1.60%$451.63REGN+0.33%$609.94ARGX-1.63%$877.72ALNY-1.64%$278.09RVMD+3.31%$162.99MRNA+3.50%$63.96UTHR-2.70%$536.59BNTX-1.44%$90.89
Snapshot
Index-P/E-EPS (ttm)
-
Insider Own17.05%
Shs Outstand154.73M
Perf Week0.63%
Market Cap6.17BForward P/E-EPS next Y-1.81Insider Trans0.22%Shs Float-Perf Month0.81%
Enterprise Value6.11BPEG3.39EPS next Q-0.40Inst Own-Short Float-Perf Quarter41.21%
Income-252313894.00P/S0.00EPS this Y-Inst Trans-Short Ratio-Perf Half Y55.60%
Sales-P/B12.56EPS next Y-7.40%ROA-39.05%Short Interest-Perf YTD60.02%
Book/sh3.15P/C-EPS next 5Y-ROE-60.37%52W High40.26 -0.60%Perf Year217.62%
Cash/sh1.79P/FCF-EPS past 3/5Y-ROIC-42.41%52W Low12.30 225.37%Perf 3Y-
Dividend Est.-EV/EBITDA-23.47Sales past 3/5Y-Gross Margin0.00%Volatility0.30% 0.29%Perf 5Y-
Dividend TTM-EV/Sales0.00EPS Y/Y TTM26.70%Oper. Margin0.00%ATR (14)0.20Perf 10Y-
Dividend Ex-Date-Quick Ratio9.53Sales Y/Y TTM-Profit Margin0.00%RSI (14)69.13Recom3.00
Dividend Gr. 3/5Y-Current Ratio9.53EPS Q/Q-52.94%SMA200.58%Beta1.21Target Price39.50
Payout0.00%Debt/Eq0.02Sales Q/Q-100.00%SMA500.91%Rel Volume3.16Prev Close39.87
Employees77LT Debt/Eq0.02EarningsAug 11SMA20038.18%Avg Volume1.76MPrice40.02
IPO DateMay 28, 2021Option/ShortYes / YesEPS/Sales Surpr.-36.84% -Net Debt/EBITDA0.21Volume5,550,696Change0.38%
Analyst Ratings
DateActionAnalystRatingTarget
Apr-20-26DowngradeWells FargoOverweight → Equal Weight$31 → $42
Apr-02-26DowngradeGuggenheimBuy → Neutral
Apr-01-26DowngradeLeerink PartnersOutperform → Market Perform
Mar-31-26DowngradeNeedhamBuy → Hold
Mar-31-26DowngradeWolfe ResearchOutperform → Peer Perform
Feb-23-26InitiatedWolfe ResearchOutperform$40
Jan-29-26ReiteratedTruist Financial$33 → $38
Jan-08-26ReiteratedTruist Financial$30 → $33
Jan-05-26ReiteratedNeedham$35 → $38
Dec-01-25ReiteratedB.Riley Financial$42
Latest News
Jun-17-26
Jun-17-2601:35PM
7 Health Care Stocks With Whale Alerts In Today's SessionBenzinga
Company
Ownership

Per-holder 13F data hasn't been ingested for this ticker yet.

Financial Statements
DataTimeframe
Line Item (USD, M)
FY 2025
12/31/2025
FY 2024
12/31/2024
FY 2023
12/31/2023
FY 2022
12/31/2022
FY 2021
12/31/2021
FY 2020
12/31/2020
FY 2019
12/31/2019
Total Revenue1507
Upgrade your experience to unlock full historical data
Cost of Goods Sold Incl. D&A
000
Gross Profit1507
Selling, General and Administrative Excl. Other505154
Research and Development172150124
Other Operating Expense100
Operating Income-208-201-171
Interest Expense111010
Unusual Expense
———
Non-Operating Income (Expense)-2322-5
Net Income Before Taxes-196-233-176
Income Taxes23-25
Consolidated Net Income-198-236-151
Net Income From Continuing Operations-198-236-151
Net Income-198-236-151
EPS (Recurring)-1.46-2.06-1.57
EPS (Basic, Before Extraordinaries)-1.46-2.06-1.57
EPS (Diluted)-1.46-2.06-1.57
EBITDA-183-222-165
Other After Tax Adjustments
———
Stock Option Compensation Expense
———
Price To Earnings Ratio
———
Price To Sales Ratio226.76——
Gross Margin100.00—100.00
Operating Margin-1,386.67—-2,442.86
Net Margin-1,320.00—-2,157.14
Shares Outstanding13611496
Market Capitalization3,401——
Operating Lease Expense
———
Insider Trading Volume
$44.05$39.80$35.55$31.29$27.04● Close Price0.00M2.29M4.57M6.86M9.14MUSD Trades VolumeJunJulAugSepOctNovDec2026FebMarAprMayJun
Insider Trading
InsiderRelationshipDateTransactionCost#SharesValue ($)#Shares TotalSEC Form 4
Anderson Karen M.Chief People OfficerMar 26 '26Sale30.1241,0761,237,38262,085Mar 27 12:00 AM
Anderson Karen M.Chief People OfficerMar 26 '26Option Exercise8.0182,152658,038103,161Mar 27 12:00 AM
Weinhoff Gregory MChief Business OfficerMar 26 '26Option Exercise3.8547,996184,78489,923Mar 26 12:00 AM
Weinhoff Gregory MChief Business OfficerMar 26 '26Sale30.0023,998719,94065,925Mar 26 12:00 AM
Anderson Karen M.Chief People OfficerMar 17 '26Option Exercise4.0120,08680,54475,000Mar 18 12:00 AM
Anderson Karen M.Chief People OfficerMar 17 '26Sale28.1010,043282,21062,085Mar 18 12:00 AM
Anderson Karen M.Chief People OfficerMar 16 '26Sale28.2164,7681,826,96962,085Mar 18 12:00 AM
Anderson Karen M.Chief People OfficerMar 16 '26Option Exercise4.01129,536519,440126,853Mar 18 12:00 AM
Anderson Karen M.Chief People OfficerMar 13 '26Option Exercise4.00437,5921,749,888182,114Mar 16 12:00 AM
Anderson Karen M.Chief People OfficerMar 13 '26Sale26.25120,0293,150,67362,085Mar 13 12:00 AM
Weinhoff Gregory MChief Business OfficerMar 13 '26Sale26.3373,1961,927,13165,925Mar 13 12:00 AM
HUSSAIN IQBAL JChief Legal OfficerFeb 02 '26Sale25.1538,951979,65757,645Feb 03 12:00 AM
HUSSAIN IQBAL JChief Legal OfficerJan 30 '26Sale25.011,01025,261104,376Feb 03 12:00 AM
Accardi Mario AlbertoPresident, Orexin ProgramDec 09 '25Sale28.8310,000288,289178,801Dec 09 12:00 AM
Accardi Mario AlbertoPresident, Orexin ProgramDec 08 '25Option Exercise9.5310,00095,300198,801Dec 08 12:00 AM
open in yahoo·open in reuters·open in marketwatch·open in google·open in EDGAR